Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The new immunosuppression: intervention at the dendritic cell-T-cell interface.

A M Paterson1, S F Yates, K F Nolan

  • 1Sir William Dunn School of Pathology, University of Oxford, South Parks Road, UK. alison.paterson@path.ox.ac.uk

Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|December 27, 2005
PubMed
Summary

Dendritic cells (DCs) are key regulators of immune responses. Understanding their interaction with T-cells is crucial for developing new immunosuppressive therapies for autoimmune diseases and transplantation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poisoning by "Kurwa Thumree"-Cucarbita Sagenaria.

The Indian medical gazette·2017
Same author

Transplantation tolerance: the big picture. Where do we stand, where should we go?

Clinical and experimental immunology·2017
Same author

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.

Leukemia & lymphoma·2016
Same author

Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response.

Immunology today·2014
Same author

Limiting dilution analysis of cells of the immune system II: What can be learnt?

Immunology today·2014
Same author

Advantages of rat monoclonal antibodies.

Immunology today·2014

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Dendritic cells (DCs) are critical in orchestrating T-cell responses, determining whether immunity or tolerance is induced.
  • Current immunosuppressive strategies aim to establish a 'tolerogenic context' for antigen presentation.
  • This approach holds promise for reducing long-term drug dependency in conditions like organ transplantation, hypersensitivity, and autoimmune diseases.

Purpose of the Study:

  • To review the biological mechanisms governing the interaction between dendritic cells and T-cells.
  • To highlight therapeutic drugs that target key molecules involved in DC-T-cell communication and function.

Main Methods:

  • Literature review of scientific articles and clinical studies.
  • Analysis of the immunological roles of dendritic cells and T-cells.

Related Experiment Videos

  • Examination of the molecular targets of existing and emerging immunosuppressive drugs.

    • Main Results:

    • Dendritic cells act as crucial initiators and directors of T-cell-mediated immunity or tolerance.
    • Targeting specific molecules in the DC-T-cell interface offers a promising strategy for therapeutic intervention.
    • Understanding this interplay is fundamental for designing effective immunosuppressive treatments.

    Conclusions:

    • Modulating the DC-T-cell interaction is a key goal for novel immunosuppressive therapies.
    • Therapeutic targeting of DC-T-cell pathways can potentially minimize the need for chronic immunosuppression.
    • Further research into these interactions will advance treatments for transplantation and autoimmune disorders.